Recent Research Funding

We receive funding from a variety of sources that recognize the value of our high-impact research.

Manav Batra, MBBS

  • Semaglutide and Dapagliflozin in Type 1 Diabetes. Manav Batra (Co-Investigator). Juvenile Diabetes Research Foundation. 3/2/2022-3/2/2022.

Ajay Chaudhuri, MBBS, MRCP(UK),FACE

  • A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study. Ajay Chaudhuri (Principal Investigator). Spruce Biosciences. 7/1/2020-7/1/2021.
  • Liraglutide Hospital Discharge Trial: A Randomized Controlled Trial Comparing the. Ajay Chaudhuri (Principal Investigator). Novo Nordisk. 3/1/2017-12/1/2020.

Husam Ghanim, PhD

  • Preserving Lean Body Mass During Weight Loss In Elderly Obese Patients With GLP-1 Receptor Agonist Treatment. Husam Ghanim (Principal Investigator). CTSI. $50,000. 12/1/2021-12/1/2022.
  • Triple therapy for T1DM with insulin, semaglutide and dapagliflozin. Husam Ghanim (Co-Principal Investigator). JDRF. $1,641,000. 1/1/2019-12/1/2023.
  • An Investigation into the effects of Dapagliflozin on Ketogensis in Type 1 Diabetes. Husam Ghanim (Co-Investigator). AstraZeneca Pharmaceuticals LP. $735,000. 1/1/2018-12/1/2022.